895244-45-8

Upstream product

• 6702-50-7 3-hydroxy-4-methoxybenzoate 
• 107-04-0 1-Bromo-2-chloroethane 
• 621-59-0 isovanillin 
• 165121-44-8 3-(2-chloroethoxy)-4-methoxybenzaldehyde 
• 67-56-1 methanol 
• 1176169-43-9 C₁₀H₁₁ClO₄ 

Downstream Products

• 1188906-89-9 methyl 5-(2-chloroethoxy)-4-methoxy-2-nitrobenzoate 
• 1445861-29-9 4-(3'-chloro-4'-fluorophenylamino)-6-[2-(2-oxa-6-azaspiro[3.3]heptane-6-yl)oxethyl]-7-methoxyquinazoline 
• 1456070-09-9 C₂₂H₂₂ClFN₄O₃ 
• 1456070-10-2 C₂₂H₂₂ClFN₄O₂S 
• 1456070-11-3 C₂₂H₂₂ClFN₄O₄S 
• 808793-73-9 4-(3-chloro-4-fluorophenylamino)-7-methoxy-6-(2-chloroethoxy)quinazoline 
• 1456070-12-4 C₂₀H₂₀ClFN₄O₃ 
• 1456070-13-5 C₂₁H₂₂ClFN₄O₃ 
• 1188906-92-4 1-(5-tert-butylisoxazol-3-yl)-3-(3-(6-(2-chloroethoxy)-7-methoxyquinazolin-4-yloxy)phenyl)urea 
• 1188906-90-2 methyl 2-amino-5-(2-chloroethoxy)-4-methoxybenzoate 
• 1188906-96-8 1-(5-tert-butylisoxazol-3-yl)-3-(3-(7-methoxy-6-(2-morpholinoethoxy)quinazolin-4-yloxy)phenyl)urea 

Relevant academic research and scientific papers

4-Quinazolinyloxy-diaryl ureas as novel BRAFV600E inhibitors

Aryl phenyl ureas with a 4-quinazolinoxy substituent at the meta-position of the phenyl ring are potent inhibitors of mutant and wild type BRAF kinase. Compound 7 (1-(5-tert-butylisoxazol-3-yl)-3-(3-(6,7-dimethoxyquinazolin-4-yloxy) phenyl)urea hydrochloride) exhibits good pharmacokinetic properties in rat and mouse and is efficacious in a mouse tumor xenograft model following oral dosing.

Four-membered heterocycles-containing 4-anilino-quinazoline derivatives as epidermal growth factor receptor (EGFR) kinase inhibitors

We report herein the design and synthesis of novel azaspirocycle or azetidine substituted 4-anilinoquinazoline derivatives. The EGFR inhibitory activities and in vitro antitumor potency of these newly synthesized compounds against two lung cancer cell lines HCC827 and A549 were evaluated. Most of the target compounds possess good inhibitory potency. In particular, compounds 21g with 2-oxa-6-azaspiro[3.4]octane substituent was found to possess higher EGFR inhibitory activities and similar antitumor potency comparing to the lead compound gefitinib with improved water solubility.

QUINAZOLINE DERIVATIVES AS RAF KINASE MODULATORS AND METHODS OF USE THEREOF

Compounds according to formula (I), compositions and methods are provided for modulating the activity of RAF kinases, including BRAF kinase and for the treatment, prevention, or amelioration of one or more symptoms of disease or disorder mediated by RAF kinases. Formula (I): or a pharmaceutically acceptable salt, solvate, clathrate of hydrate thereof, wherein X is O or S(O)t; Ra is O or S.